Published in Leukemia on April 10, 2008
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol (2010) 4.26
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 2.39
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood (2012) 1.96
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood (2009) 1.74
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell (2015) 1.52
Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia (2008) 1.51
Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med (2012) 1.40
Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov (2013) 1.39
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood (2009) 1.28
The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med (2010) 1.18
Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res (2009) 1.13
Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci (2014) 1.10
Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol (2009) 1.09
Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood (2012) 1.07
Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program (2010) 1.01
More epigenetic hits than meets the eye: microRNAs and genes associated with the tumorigenesis of retinoblastoma. Front Genet (2012) 0.99
How I treat the peripheral T-cell lymphomas. Blood (2014) 0.97
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica (2013) 0.96
Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma. Blood (2012) 0.96
New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res (2010) 0.94
Treatment of peripheral T-cell lymphoma: are we data driven or driving the data? Curr Treat Options Oncol (2013) 0.93
Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations. Haematologica (2010) 0.91
Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines. Leukemia (2009) 0.90
Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer. Biochim Biophys Acta (2014) 0.89
A peptide-based biosensor assay to detect intracellular Syk kinase activation and inhibition. Biochemistry (2012) 0.89
New targets of therapy in T-cell lymphomas. Curr Drug Targets (2010) 0.89
The lymphoma-associated fusion tyrosine kinase ITK-SYK requires pleckstrin homology domain-mediated membrane localization for activation and cellular transformation. J Biol Chem (2009) 0.86
Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas. Blood Cancer J (2013) 0.85
Syk interacts with and phosphorylates nucleolin to stabilize Bcl-x(L) mRNA and promote cell survival. Mol Cell Biol (2014) 0.84
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified. Blood Cancer J (2014) 0.82
Follicular helper T cells: implications in neoplastic hematopathology. Semin Diagn Pathol (2011) 0.81
Angioimmunoblastic T-cell lymphoma in Taiwan shows a frequent gain of ITK gene. Int J Clin Exp Pathol (2014) 0.80
Peripheral T cell lymphoma: new model + new insight. J Exp Med (2010) 0.79
A three-signal model of T-cell lymphoma pathogenesis. Am J Hematol (2015) 0.78
Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia. Oncotarget (2015) 0.77
New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008. J Hematop (2008) 0.76
Burrowing through the Heterogeneity: Review of Mouse Models of PTCL-NOS. Front Oncol (2016) 0.75
Spleen tyrosine kinase contributes to acute renal allograft rejection in the rat. Int J Exp Pathol (2014) 0.75
E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia. Cancer Res (2016) 0.75
Follicular variant of peripheral T cell lymphoma with mediastinal involvement in a child: a case report. Virchows Arch (2015) 0.75
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood (2007) 3.52
Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today (2000) 2.43
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood (2006) 2.32
Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia (2006) 2.24
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol (2004) 2.23
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol (2006) 2.09
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol (2007) 1.91
Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol (1994) 1.80
Syk-dependent mTOR activation in follicular lymphoma cells. Blood (2006) 1.68
Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer (2005) 1.53
B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase. J Immunol (2000) 1.51
The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol (2006) 1.40
Phosphorylation of Syk activation loop tyrosines is essential for Syk function. An in vivo study using a specific anti-Syk activation loop phosphotyrosine antibody. J Biol Chem (2000) 1.26
Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol (2005) 1.26
Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther (2005) 1.23
Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood (2005) 1.22
Functional role for Syk tyrosine kinase in natural killer cell-mediated natural cytotoxicity. J Exp Med (1997) 1.18
Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol (2007) 1.14
Peripheral T-cell lymphoma with follicular involvement and a CD4+/bcl-6+ phenotype. Am J Surg Pathol (2001) 1.10
Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia (2007) 1.08
Differential regulation by leukotrienes and calcium of Fc gamma receptor-induced phagocytosis and Syk activation in dendritic cells versus macrophages. J Leukoc Biol (2006) 0.96
Altered expression of tyrosine kinases of the Src and Syk families in human T-cell leukemia virus type 1-infected T-cell lines. J Virol (1999) 0.93
Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma. Leukemia (2005) 0.85
Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples. Br J Haematol (2004) 0.84
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
COSMIC 2005. Br J Cancer (2006) 5.07
Lymphoid neogenesis in rheumatoid synovitis. J Immunol (2001) 3.63
Promoter specificity of sigma G-containing RNA polymerase from sporulating cells of Bacillus subtilis: identification of a group of forespore-specific promoters. J Bacteriol (1989) 2.13
Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet (2001) 1.97
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia (2011) 1.92
Sclerosing extramedullary hematopoietic tumor in chronic myeloproliferative disorders. Am J Surg Pathol (2000) 1.79
Is stenting necessary after balloon dilation of post-transplantation biliary strictures? Results of a prospective comparative study. Endoscopy (2008) 1.76
HIV infection and lymphoma. J Clin Pathol (2007) 1.67
Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene (2003) 1.63
Overlapping PCR for bidirectional PCR amplification of specific alleles: a rapid one-tube method for simultaneously differentiating homozygotes and heterozygotes. Genome Res (1997) 1.60
Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood (1996) 1.53
Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. Arch Dermatol (2001) 1.53
Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia (2008) 1.51
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia (2007) 1.51
Small B-cell lymphoid neoplasms with coexisting T-cell lymphomas. Am J Clin Pathol (1992) 1.51
The role of CD8+ CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. J Immunol (1998) 1.50
Towards an evidence-based process for the clinical interpretation of copy number variation. Clin Genet (2011) 1.50
Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc (1993) 1.47
Ectopic lymphoid organogenesis: a fast track for autoimmunity. Am J Pathol (2001) 1.46
Utility of multicolor fluorescent in situ hybridization in clinical cytogenetics. Genet Med (2001) 1.45
Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol (2001) 1.44
Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am J Surg Pathol (1999) 1.43
Malignant lymphoma of the bladder: evidence from 36 cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma. Am J Surg Pathol (1997) 1.42
Bowel perforation in intestinal lymphoma: incidence and clinical features. Ann Oncol (2013) 1.41
Successful pregnancy and birth after transfer of donated embryo fertilized in vitro. Chin Med J (Engl) (1988) 1.41
Megaloblastic pancytopenia associated with dapsone and trimethoprim treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med (1989) 1.40
Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol (2000) 1.38
Evidence that intergenic spacer repeats of Drosophila melanogaster rRNA genes function as X-Y pairing sites in male meiosis, and a general model for achiasmatic pairing. Genetics (1992) 1.37
Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol (1998) 1.37
Immunoglobulin specificity of low grade B cell gastrointestinal lymphoma of mucosa-associated lymphoid tissue (MALT) type. Am J Pathol (1993) 1.36
Hepatitis C virus and lymphoma. J Clin Pathol (2007) 1.33
Traumatic brain injury leads to increased expression of peripheral-type benzodiazepine receptors, neuronal death, and activation of astrocytes and microglia in rat thalamus. Exp Neurol (2000) 1.32
Laryngeal amyloidosis: a clinicopathologic and immunohistochemical review. Otolaryngol Head Neck Surg (1992) 1.32
Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol (2001) 1.31
Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol (2002) 1.31
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia (2012) 1.27
Validation of immunoglobulin gene rearrangement detection by PCR using commercially available BIOMED-2 primers. Leukemia (2006) 1.27
T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood (2001) 1.26
Primary spinal epidural non-Hodgkin's lymphoma: report of eight patients and review of the literature. Neurosurgery (1992) 1.24
Antisense knockdown of the glial glutamate transporter GLT-1, but not the neuronal glutamate transporter EAAC1, exacerbates transient focal cerebral ischemia-induced neuronal damage in rat brain. J Neurosci (2001) 1.24
Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant (2006) 1.20
Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol (2005) 1.16
Posttransplant primary CNS lymphoma. Neuro Oncol (2000) 1.16
Death from inappropriate therapy for Lyme disease. Clin Infect Dis (2000) 1.15
Chromosomal microarray impacts clinical management. Clin Genet (2013) 1.13
BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. Am J Pathol (2000) 1.13
Acute myeloid leukemia with minimal differentiation. A multiple parameter study. Am J Clin Pathol (1998) 1.13
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia (2012) 1.12
Atypical carcinoid of the lung. A distinct clinicopathologic entity. Chest (1988) 1.11
The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol (2000) 1.10
Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia (2007) 1.08
Routine acid decalcification of bone marrow samples can preserve DNA for FISH and CGH studies in metastatic prostate cancer. J Histochem Cytochem (2002) 1.08
The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant (2007) 1.08
Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med (1989) 1.07
Lymphomatoid granulomatosis. Evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection. Am J Surg Pathol (1995) 1.06
Fluorescence in situ hybridization with X and Y chromosome probes for cytogenetic studies on bone marrow cells after opposite sex transplantation. Bone Marrow Transplant (1993) 1.05
Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. Am J Clin Pathol (1999) 1.05
A catabolite-resistance mutation is localized in the rpo operon of Bacillus subtilis. Can J Microbiol (1984) 1.05
Neurological complications of peripheral and cutaneous T-cell lymphomas. Ann Neurol (1994) 1.03
BCL10 gene mutation in lymphoma. Blood (2000) 1.01
Dedifferentiated liposarcoma: a report of nine cases with a peculiar neurallike whorling pattern associated with metaplastic bone formation. Am J Surg Pathol (1998) 1.01
Cell-cell interactions in synovitis. Interactions between T cells and B cells in rheumatoid arthritis. Arthritis Res (2000) 1.01
T-cell-rich B-cell lymphomas: diagnosis and response to therapy of 44 patients. J Clin Oncol (1995) 1.01
Incidental findings in pelvic lymph nodes at radical prostatectomy. J Clin Pathol (2002) 1.01
Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. J Mol Diagn (2000) 1.01
Pulmonary marginal zone lymphoma of MALT type as a cause of localised pulmonary amyloidosis. J Clin Pathol (2001) 1.00
Nonimmunoglobulin gene hypermutation in germinal center B cells. Blood (1999) 1.00
Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol (2000) 1.00
TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol (1997) 0.99
Antisense knockdown of the glial glutamate transporter GLT-1 exacerbates hippocampal neuronal damage following traumatic injury to rat brain. Eur J Neurosci (2001) 0.99
Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues. Am J Clin Pathol (1991) 0.99
Immunoproliferative small-intestinal disease. An immunohistochemical study. Am J Surg Pathol (1989) 0.99
Cloning and nucleotide sequencing of genes for a second type of small, acid-soluble spore proteins of Bacillus cereus, Bacillus stearothermophilus, and "Thermoactinomyces thalpophilus". J Bacteriol (1987) 0.97
Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia (2005) 0.97
The rates and patterns of deletions in the human factor IX gene. Am J Hum Genet (1994) 0.96
Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood (1999) 0.96
Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology (2007) 0.95
Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res (2001) 0.95
Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia (2004) 0.95
Absence of bcl-2 major breakpoint region and JH gene rearrangement in lymphocyte predominance Hodgkin's disease. Results of Southern blot analysis and polymerase chain reaction. Am J Pathol (1991) 0.94
Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). Leukemia (1997) 0.93
Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets. Leukemia (2010) 0.93
Extrathymic T cell differentiation in the human intestine early in life. J Immunol (1998) 0.93
T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas. Am J Pathol (1998) 0.93
The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis. Curr Opin Rheumatol (2003) 0.92
Hepatitis C transmission by cosmetic tattooing in women. Lancet (1996) 0.92
Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. Gastroenterology (1991) 0.92
Base-specific sequences that bias somatic hypermutation deduced by analysis of out-of-frame human IgVH genes. J Immunol (1998) 0.92